135 related articles for article (PubMed ID: 38240344)
1. DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia.
Mishra SV; Banerjee A; Sarkar D; Thangarathnam V; Bagal B; Hasan SK; Dutt S
J Cell Sci; 2024 Feb; 137(3):. PubMed ID: 38240344
[TBL] [Abstract][Full Text] [Related]
2. High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia.
Song JH; Kweon SH; Kim HJ; Lee TH; Min WS; Kim HJ; Kim YK; Hwang SY; Kim TS
Br J Cancer; 2012 Jun; 107(1):108-15. PubMed ID: 22627319
[TBL] [Abstract][Full Text] [Related]
3. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
[TBL] [Abstract][Full Text] [Related]
4. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
5. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
6. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
7. p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase.
Fedier A; Moawad A; Haller U; Fink D
Int J Oncol; 2003 Nov; 23(5):1431-7. PubMed ID: 14532987
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
9. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome.
Prebet T; Lhoumeau AC; Arnoulet C; Aulas A; Marchetto S; Audebert S; Puppo F; Chabannon C; Sainty D; Santoni MJ; Sebbagh M; Summerour V; Huon Y; Shin WS; Lee ST; Esterni B; Vey N; Borg JP
Blood; 2010 Sep; 116(13):2315-23. PubMed ID: 20558616
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2β.
Herold N
Expert Opin Drug Discov; 2021 Jan; 16(1):7-11. PubMed ID: 32866407
[No Abstract] [Full Text] [Related]
11. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
Long X; Yu Y; Perlaky L; Man TK; Redell MS
Br J Haematol; 2015 Sep; 170(5):704-18. PubMed ID: 25974135
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
13. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
14. Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.
Massaad-Massade L; Ribrag V; Marie JP; Faussat AM; Bayle C; Dreyfus F; Gouyette A
Anticancer Res; 1997; 17(6D):4647-51. PubMed ID: 9494583
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Hermanson DL; Das SG; Li Y; Xing C
Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
[TBL] [Abstract][Full Text] [Related]
16. Assessing acute myeloid leukemia susceptibility in rearrangement-driven patients by DNA breakage at topoisomerase II and CCCTC-binding factor/cohesin binding sites.
Atkin ND; Raimer HM; Wang Z; Zang C; Wang YH
Genes Chromosomes Cancer; 2021 Dec; 60(12):808-821. PubMed ID: 34405474
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.
Lal D; Park JA; Demock K; Marinaro J; Perez AM; Lin MH; Tian L; Mashtare TJ; Murphy M; Prey J; Wetzler M; Fetterly GJ; Wang ES
Mol Cancer Ther; 2010 Oct; 9(10):2737-51. PubMed ID: 20924124
[TBL] [Abstract][Full Text] [Related]
18. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
[TBL] [Abstract][Full Text] [Related]
19. Chromatin regulators mediate anthracycline sensitivity in breast cancer.
Seoane JA; Kirkland JG; Caswell-Jin JL; Crabtree GR; Curtis C
Nat Med; 2019 Nov; 25(11):1721-1727. PubMed ID: 31700186
[TBL] [Abstract][Full Text] [Related]
20. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
